(NASDAQ: ELTX) Elicio Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.57%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.87%.
Elicio Therapeutics's earnings in 2024 is -$38,663,000.On average, 2 Wall Street analysts forecast ELTX's earnings for 2024 to be -$36,471,933, with the lowest ELTX earnings forecast at -$39,003,958, and the highest ELTX earnings forecast at -$33,939,908. On average, 2 Wall Street analysts forecast ELTX's earnings for 2025 to be -$32,646,959, with the lowest ELTX earnings forecast at -$33,724,417, and the highest ELTX earnings forecast at -$31,569,502.
In 2026, ELTX is forecast to generate -$30,492,044 in earnings, with the lowest earnings forecast at -$30,492,044 and the highest earnings forecast at -$30,492,044.